CClinicalTrials.gg
CompletedNCT06522724Updated Nov 6, 2024

Education Impact on Rehabilitation of Hospitalized Patients With Pneumonia and COVID-19

An interventional study of Education program and Pulmonary rehabilitation in Pneumonia Due to COVID-19, sponsored by University of Rzeszow. Completed at 1 site in Poland. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by University of Rzeszow · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

The planned research will enable the assessment of rehabilitation's effects using two pulmonary rehabilitation models: conventional and supplemented with an education program for patients hospitalized due to pneumonia with confirmed COVID-19.

Read the detailed description

The planned group size is 60 patients diagnosed with pneumonia and confirmed COVID-19. The given population was calculated based on the sampling calculator, considering the following parameters: fraction size, confidence level, and maximum error. Eligible patients will be randomly divided into two groups: a study group (30 patients) undergoing pulmonary rehabilitation supplemented with an education program, and a control group (30 patients) undergoing conventional pulmonary rehabilitation. Patients of both groups will be included in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of three hours daily. The program will be applied individually to each patient and include in-bed assisted exercises, airway clearance techniques, effective cough exercises, pursed-lips breathing, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises. Patients from the study group will additionally undergo daily education using an original brochure containing information about self management during the treatment process, the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise. The test will be performed two times: before the start of rehabilitation and after completing the rehabilitation program. The patients' condition and the rehabilitation effects will be assessed using the following measures:

  • Vital capacity (Voldyne 5000)
  • Oxygen saturation (pulse oximeter)
  • Acid-base balance (gasometry)
  • Fatigue (modified Borg scale)
  • Physical performance (Sit-to-Stand Test)
  • Dyspnea assessment (MRC dyspnea scale)
  • Anxiety and depression (HADS scale)
  • Activities of daily living (Barthel scale)
02

Conditions studied

  • Pneumonia Due to COVID-19

Keywords

  • pulmonary rehabilitation
  • COVID-19
  • pneumonia
  • patients' education
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 100 is close to the median of 100 across 4,099 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

University of Rzeszow is the lead sponsor of 37 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Hospitalization due to pneumonia due to COVID-19
  • Positive SARS-COV-2 PCR test
  • Independence in in-bed sitting position with lower extremities placed on the floor
  • Age 40 y.o. to 70 y.o.
  • No additional respiratory support (e.a. cardiopulmonary bypass machine, ventilator)
  • Informed, voluntary consent to participate in research.

Exclusion criteria

Exclusion Criteria:

  • Hospitalization due to pneumonia with negative SARS-COV-2 PCR test
  • Unstable medical condition hindering performing the examination
  • Age under 40 y.o. and over 70 y.o.
  • Cognitive deficits impairing the ability to understand and execute commands
  • Concomitant oncological, neurological, orthopedic, and psychiatric diseases may affect the examined persons' circulatory and respiratory functions, functional efficiency, quality of life, and emotional state.
  • Failure to complete a 14-day rehabilitation program
  • Lack of informed, voluntary consent to participate in research
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Education program and Pulmonary rehabilitation

    Conventional pulmonary rehabilitation coupled with original education program.

    Other: Education program · Other: Pulmonary rehabilitation

  • Other
    Pulmonary rehabilitation

    Conventional pulmonary rehabilitation

    Other: Pulmonary rehabilitation

Interventions

  • OtherEducation program

    Patients in a study group will participate in daily education program using an original brochure containing information about self-management during the treatment process, the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise.

  • OtherPulmonary rehabilitation

    The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of three hours daily. The program will be applied individually to each patient and include in-bed assisted exercises, airway clearance techniques, effective cough exercises, pursed-lips breathing, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.

06

What researchers measure

Primary outcomes

  1. Vital capacity (Voldyne 5000)

    Measurements will be performed with certified motivational spirometer, Voldyne 5000. Patient, in a sitting position, will inhale as much air as possible starting from residual volume (RV) level and approach to vital capacity (VC) level. The result will be read from the scale placed on the wall of the device.

    Time frame: First examination- before the start of the 14-day rehabilitation program

  2. Vital capacity (Voldyne 5000)

    Measurements will be performed with certified motivational spirometer, Voldyne 5000. Patient, in a sitting position, will inhale as much air as possible starting from residual volume (RV) level and approach to vital capacity (VC) level. The result will be read from the scale placed on the wall of the device.

    Time frame: Second examination- at the end of the 14-day rehabilitation program

  3. Oxygen saturation

    Measurements will be performed with pulse oximeter and the parameter analyzed will be SpO2 (oxygen saturation by pulse oximetry; percentage of oxygen in patients' blood).

    Time frame: First examination- before the start of the 14-day rehabilitation program

  4. Oxygen saturation

    Measurements will be performed with pulse oximeter and the parameter analyzed will be SpO2 (oxygen saturation by pulse oximetry; percentage of oxygen in patients' blood).

    Time frame: Second examination- at the end of the 14-day rehabilitation program

  5. Acid-base balance

    The gasometry results will be taken from patients' medical documentation. The parameters analyzed will be oxygen pressure (pO2) and carbon dioxide pressure (pCO2).

    Time frame: First examination- before the start of the 14-day rehabilitation program

  6. Acid-base balance

    The gasometry results will be taken from patients' medical documentation. The parameters analyzed will be oxygen pressure (pO2) and carbon dioxide pressure (pCO2).

    Time frame: Second examination- at the end of the 14-day rehabilitation program

Secondary outcomes

  1. Physical performance assessment by Sit-to-Stand Test (STS)

    The test will be performed starting in sitting position in the chair with straight back, feet flat on the floor, and arms crossed over the chest or placed on the thighs. The patient will be instructed to stand up fully from the seated position and then sit back down as quickly and safely as possible during 30 seconds (number of standings in 30 seconds).

    Time frame: First examination- before the start of the 14-day rehabilitation program

  2. Physical performance assessment by Sit-to-Stand Test (STS)

    The test will be performed starting in sitting position in the chair with straight back, feet flat on the floor, and arms crossed over the chest or placed on the thighs. The patient will be instructed to stand up fully from the seated position and then sit back down as quickly and safely as possible during 30 seconds (number of standings in 30 seconds).

    Time frame: Second examination- at the end of the 14-day rehabilitation program

  3. Fatigue assessment using modified Borg scale

    Fatigue will be examined during physical activity and the level of fatigue will be marked on a scale from 1 (no fatigue) to 10 (very very hard fatigue).

    Time frame: First examination- before the start of the 14-day rehabilitation program

  4. Fatigue assessment using modified Borg scale

    Fatigue will be examined during physical activity and the level of fatigue will be marked on a scale from 1 (no fatigue) to 10 (very very hard fatigue).

    Time frame: Second examination- at the end of the 14-day rehabilitation program

  5. Dyspnea assessment with Medical Research Council dyspnea scale

    Perceived breathlessness degree will be marked on a scale 0 (no breathlessness) to 4 (breathlessness at rest).

    Time frame: First examination- before the start of the 14-day rehabilitation program

  6. Dyspnea assessment with Medical Research Council dyspnea scale

    Perceived breathlessness degree will be marked on a scale 0 (no breathlessness) to 4 (breathlessness at rest).

    Time frame: Second examination- at the end of the 14-day rehabilitation program

  7. Anxiety and depression assessment using HADS scale

    The scale consists of 16 statements to which the respondent refers on a four-point scale. Eight statements are used to measure anxiety and depression, each of which is rated on a scale of 0 to 3 points. The cut-off threshold is 7 points for depression and 7 points for anxiety. The intensity of depressed mood and anxiety will be analyzed.

    Time frame: First examination- before the start of the 14-day rehabilitation program

  8. Anxiety and depression assessment using HADS scale

    The scale consists of 16 statements to which the respondent refers on a four-point scale. Eight statements are used to measure anxiety and depression, each of which is rated on a scale of 0 to 3 points. The cut-off threshold is 7 points for depression and 7 points for anxiety. The intensity of depressed mood and anxiety will be analyzed.

    Time frame: Second examination- at the end of the 14-day rehabilitation program

  9. Activities of daily living assesment using Barthel scale

    The Barthel Scale will be used to measure patient's ability to perform activities of daily living (ADLs) independently, with scores ranging from 0 (completely dependent) to 100 (completely independent).

    Time frame: First examination- before the start of the 14-day rehabilitation program

  10. Activities of daily living assesment using Barthel scale

    The Barthel Scale will be used to measure patient's ability to perform activities of daily living (ADLs) independently, with scores ranging from 0 (completely dependent) to 100 (completely independent).

    Time frame: Second examination- at the end of the 14-day rehabilitation program

07

Study locations

1 site
  • University of Rzeszów
    Rzeszów, 35-959, Poland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06522724
Lead sponsor
University of Rzeszow
Responsible party
Renata Borys (MSc, University of Rzeszow) — Principal investigator
First posted
Jul 26, 2024
Start date
Jul 26, 2024
Primary completion
Sep 26, 2024
Completion
Oct 26, 2024
Last update
Nov 6, 2024

Study contacts

Renata Borys, MSc
principal investigator · University of Rzeszow
Agnieszka Guzik, A/Prof
study director · University of Rzeszow
Magdalena Kołodziej, PhD
study chair · University of Rzeszow

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion